Our team closely monitors your progress and adjusts the program as needed to minimize any potential side effects
Have a history of Arrhythmia: If you already have a condition like AFib, you must be closely monitored
Patients with certain genetic profiles may tolerate one medication better than the other, despite both drugs having identical safety profiles in the general population
Clinical studies show that patients using semaglutide lose significantly more weight than those on diet and exercise alone, with many achieving sustained results over 12 months or longer
This might be due to variations in patient characteristics, the severity of acne at baseline, or metabolic reactions (e.g., insulin alterations, weight loss)
#Retatrutide #ObesityTrials #DiabetesCare #Lilly #MetabolicInnovation #Phase3 To view or add a comment, sign in - The European Commission has approved Wegovy (once-daily oral semaglutide 25 mg) for adults living with obesity or overweight with at least one weight-related comorbidity, offering the first GLP-1 receptor agonist in tablet form for weight management across all EU member states
